BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat

Go back to BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.16 --0 (-0%)
Previous Close $3.16    52 Week High $1.63 
Open $3.16    52 Week Low $0.71 
Day High $3.16    P/E N/A 
Day Low $3.16    EPS $0.00 
Volume 871       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.16 --0 (-0%)
Previous Close $3.16    52 Week High $1.63 
Open $3.16    52 Week Low $0.71 
Day High $3.16    P/E N/A 
Day Low $3.16    EPS $0.00 
Volume 871